PHENOTYPIC BIOMARKERS MAY SIMPLIFY THE APPROACH TO PRECISION MEDICINE IN ADVANCED PROSTATE CANCER\(^1\-\^3\)

**The complexity of advanced prostate cancer (APC) makes the implementation of genotypic precision medicine challenging in various ways:**

| 1 CLINICAL | Bone biopsies are painful, technically difficult, and challenging to interpret.\(^5\-\^7\) |
| 2 OPERATIONAL | Optimizing test selection, biopsy technique, timing, and test result interpretation is a challenge for genotypic precision medicine.\(^8\-\^10\) |
| 3 BIOLOGIC | The majority of clinically relevant driver mutations are present in <5% of prostate cancer tumors due to the heterogeneity of the disease.\(^11\-\^15\) |

Taken together, these features of APC underlie the need for novel precision medicine approaches, including the use of **phenotypic biomarkers** that can be detected through noninvasive diagnostics such as prostate-specific membrane antigen positron emission tomography (PSMA PET) imaging.\(^16\-\^20\)

PSMA PET leverages radiotracers to visualize **PSMA-expressing** prostate cancer tissue at a high sensitivity and specificity.\(^21\-\^24\) PET imaging with radiotracers offers a phenotypic approach that may simplify the use of precision medicine in APC.\(^1\-\^3,22,24,25\)

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

**References**

PSMA IS A DIAGNOSTIC, PROGNOSTIC, AND CLINICALLY RELEVANT BIOMARKER IN ADVANCED PROSTATE CANCER

PSMA expression is an example of a **phenotypic trait**, which is defined as an observable characteristic that is produced through the interaction of a genotype and environment.\(^4\,^5\) Phenotypes can be detected through PET imaging, among other modalities.\(^6\)

**PSMA has been shown to have potential utility at multiple time points within the prostate cancer care spectrum**\(^1\,^3\,^7\):

---

**Diagnosis**

Compared with conventional imaging, PSMA PET/CT (computed tomography) was 27\% (95\% CI 23-31) more accurate (92\% [88-95] vs 65\% [60-69]; \(P<0.0001\)) for the detection of prostate cancer among patients with high-risk localized disease.\(^1\)\(^4\)

**Prognosis**

PSMA expression level was negatively correlated with 5-year recurrence-free survival (88.2\% for no expression vs 26.8\% for high expression).\(^2\)

**Clinical Management**

PSMA PET/CT results after conventional imaging may have led to management changes in up to 60\% of patients.\(^3\,^7\)

---

**PSMA PET/CT may help guide clinical management with a tailored approach**\(^3\,^4\)

---

**PSMA is overexpressed in >80\% of men with prostate cancer**\(^2\,^8\,^9\)

---

**PSMA is a diagnostic and potential therapeutic target that may enable a phenotypic precision medicine approach to managing APC.**\(^1\,^3\)

---

*The ProPSMA study was a prospective, multicenter, randomized, controlled trial of men with high-risk, apparently localized prostate cancer. Three hundred two were randomly assigned to receive either CT and bone scan (conventional imaging) or PSMA PET/CT. First-line imaging was done within 21 days of randomization. The primary end point was accuracy of first-line imaging for identifying either pelvic nodal or distant metastatic disease defined by the receiver-operating curve using a predefined reference standard including histopathology, imaging, and biochemistry at 6-month follow-up. Results for subgroups of patients with pelvic nodal (area under the curve 91\% vs 59\% [32\% absolute difference; 26–35]) and distant (95\% vs 74\% [22\% absolute difference; 18–26]) metastases also showed superiority of PSMA PET/CT.\(^3\)

**PSMA expression was assessed in a retrospective study by immunohistochemistry in 294 preoperative biopsies, 621 primary tumor foci from 242 radical prostatectomies, 43 locally advanced or recurrent tumors obtained from transurethral prostate resection, 34 lymph node metastases, 78 distant metastases, and 52 benign prostatic samples from patients who underwent surgery. PSMA expression was categorized as no expression (score of 0), low expression (1), medium expression (2), or high expression (3). Expression was correlated with recurrence-free survival as the primary end point measure. Disease recurrence was defined as biochemical recurrence (prostate-specific antigen [PSA] increase above the postoperative nadir following radical prostatectomy) and recurrence-free survival was used as the primary end point for survival analysis.\(^2\)

**The aim of the retrospective, real-world, single-institution study from Switzerland was to assess the effect of PSMA PET/CT on management and outcome in all patients imaged during the first year after its introduction into clinical routine. The rate of detection of recurrence was based on clinical reports. In the 203 patients with follow-up 6 months after PSMA PET/CT, the therapies effectively implemented as well as follow-up PSA levels were evaluated, with a PSA value of <0.2 ng/mL representing a complete response and a decrease in PSA value of at least 50\% from baseline representing a partial response.\(^3\)**

---

**References**


© 2021 Advanced Accelerator Applications. All Rights Reserved.